STOK Stoke Therapeutics Earnings and EPS analysis

Relative Growth: Rel. Growth: 10

Relative Strength: Rel. Strength: 29

Relative Valuation: Rel. Valuation: 5

Relative Profitability: Rel. Profitability: 21

EPS in 2026 (TTM): -$3.37

Last Report Period Date: Jun 30, 2026

Based on the company's latest reports for June 2026, the current 12-month EPS is -$3.37. Stoke Therapeutics's earnings per share in 2025 was reported at -$0.12, marking a rise from -$1.65 in 2024. In the quarterly report ending on Jun 30, 2026, STOK's earnings per share amounted to -$0.93.

STOK earnings history

Historical annual and quarterly earnings per share (EPS) data for Stoke Therapeutics

EPS (TTM)

-$3.37

EPS Growth YoY (Quarterly)

-132.5%

EPS (Quarterly)

-$0.93

EPS Growth (Quarterly)

-17.7%

Stoke Therapeutics had an yealy earnings per share of -$0.12, showing a rise of 92.7% from -$1.65 recorded in 2024. The quarterly earnings per share for the period ending Jun 30, 2026, was -$0.93, showing a 132.5% decline compared to the same quarter last year. The trailing twelve months EPS for STOK is -$3.37 as of June 2026. Stoke Therapeutics's full-year EPS for 2024 was -$1.65, a 30.7% rise compared to the previous year.

STOK EPS vs price chart

STOK EPS growth history

Earnings per share growth rates over time

EPS Growth YoY (Quarterly)

-132.5%

EPS growth YoY

92.7%

EPS growth 3Y avg

N/A

EPS growth 5Y avg

N/A

Stoke Therapeutics has recorded a decline in earnings per share of 132.5% in the past 12 months (YoY, quarterly).

STOK Earnings Waterfall

Breakdown of revenue, profit and net income for Stoke Therapeutics

STOK Earnings vs Peers

What are the earnings of STOK compared to its peers

Stock name	Price to Earnings	EPS grwoth 1Y	EPS grwoth 3Y	EPS grwoth 5Y
ORMP Oramed Pharmaceuticals Inc	1.12	418.8%	N/A	N/A
OMER Omeros Corp	10.86	98.1%	N/A	N/A
OLMA Olema Pharmaceuticals Inc	N/A	15%	N/A	N/A
VIVS VivoSim Labs Inc.	N/A	-214.7%	N/A	N/A
ORIC Oric Pharmaceuticals Inc	N/A	19.7%	N/A	N/A
STOK Stoke Therapeutics Inc	N/A	92.7%	N/A	N/A

All data is based on quarterly TTM periods, unless otherwise specified.